Ryan Wereski (@RyanWereski) header
Ryan Wereski (@RyanWereski) profile picture

Cardiology Registrar & Clinical Research Fellow @EdinUniCVS | Coronary disease • Biomarkers • Troponin • Data visualisation • R Studio • Statistics

Edinburgh, Scotland
Joined May 2016
Photo by Ryan Wereski (@RyanWereski)Photo by Ryan Wereski (@RyanWereski)Photo by Ryan Wereski (@RyanWereski)Photo by Ryan Wereski (@RyanWereski)Photo by Ryan Wereski (@RyanWereski)Photo by Ryan Wereski (@RyanWereski)Photo by Ryan Wereski (@RyanWereski)Photo by Ryan Wereski (@RyanWereski)Photo by Ryan Wereski (@RyanWereski)Photo by Ryan Wereski (@RyanWereski)
Pleased to share the results of our latest study evaluating the role of "High-Sensitivity Cardiac Troponin for Risk Assessment in Chronic Coronary Disease" Out now in @JACCJournals authors.elsevier.com/a/1hV-L… 1/2
2
16
1
56
7,885
In ORBITA-STAR, angina verification with an ischaemic stimulus powerfully predicted response to PCI. #EuroPCR2024 Perhaps we have been too focused on treatment when the problem always lay in the diagnosis! Published today in #JACC jacc.org/doi/10.1016/j.jacc.… @rallamee
9
76
16
251
84,315
A new and important paper from JACC on EPA and Lp(a) from REDUCE-IT. Baseline Lp(a) was highly predictive of events in people with high TG and controlled LDL-C, and risk was linear, not threshold. EPA was a/w benefit irrespective of Lp(a) levels. Expands data to people with high TGs, and also more data that Lp(a) risk is independent of LDL-C and apoB. Now we need to wait for outcomes data on Lp(a) lowering. jacc.org/doi/10.1016/j.jacc.…
4
26
2
86
14,809
"What is a normal cholesterol?" As a cardiologist, I get this question all the time. Most people are getting this all wrong. 📕Make Sure To Bookmark✅ 🧵👇 /1
21
143
2
670
259,188
Additive antithrombotic effects of PAR4 antagonism in patients with coronary artery disease receiving single or dual antiplatelet therapies @HighSTEACS @SamuelDebono @jennynashville ahajrnls.org/3Tg6LiZ
9
1
17
2,666
If PCI as a "therapy" for stable ischemic heart disease is controversial, its role as a "prevention" for vulnerable plaques is even more controversial. In a few weeks, at ACC.24, the PREVENT investigators will present the results of a multicenter, open-label, randomized controlled trial comparing preventive PCI plus medical therapy versus medical therapy alone in more than 1,600 patients with functionally insignificant (fractional flow reserve >0.80) vulnerable plaques containing multiple high-risk features. Anticipating the presentation and publication of PREVENT, we invited @dukwoo_park and @DavidLBrownMD to debate on prophylactic stenting of vulnerable plaques. eurointervention.pcronline.c…
13
86
9
290
53,945
Great Debate 🤜 🤛 @escardio Pros and Cons of the Universal Definition of Myocardial Infarction at #ESC2023 Excellent summary of the benefits and challenges when using the UDMI in practice 🏥 – at Amsterdam, The Netherlands
2
7
925
“Biomarkers do not replace clinical judgement and we must think: What is the biomarker telling me in the setting in which it was measured” @JJheart_doc @escardio @AbbottNews – at Amsterdam, The Netherlands
9
315
“Pre-operative cardiovascular risk assessment allows patients to make an informed choice about proposed surgery” @escardio @AbbottNews – at Amsterdam, The Netherlands
2
8
1,884
“Risk prediction by machines”. Excellent presentation by @chapdoc1 at @escardio #Amsterdam – at Amsterdam, The Netherlands
1
13
691
Bringing up the rear of team Edinburgh, finally en route to #ESC2023 with @RyanWereski after an honest morning’s work and an honest evening’s gin and tonic tasting 🍸 Tot snel Amsterdam and my wonderful cardiology friends 🤩 🌷 🇳🇱 @escardio @ESC_Journals – at Scotland, United Kingdom
4
2
42
2,142
The goal of the STOP-CA trial was to assess whether concomitant treatment w/ atorvastatin may prevent the reduction in LVEF that may be seen in patients w/ lymphoma receiving anthracycline-based chemotherapy. Get the trial details here ➡️ bit.ly/440Xu0n #CardioOnc
1
5
15
5,039
In patients with chronic CAD, an elevated #troponin identifies those more likely to have MI or CV death. Routine troponin testing in this setting could inform patient selection for additional treatment. bit.ly/3rZhhjp #JACC #cvCAD #CardioTwitter #cvPrev #cvMI
34
79
14,420
Latest @JACCJournals: The Evolving Role of Cardiac Troponin: From Acute to Chronic Coronary Syndromes bit.ly/456vHNc. Our editorial addressing the research by @RyanWereski @HighSTEACS et al. on hs #troponin for risk assessment in chronic CAD bit.ly/3QjSq3W
1
23
1
62
9,300
Key findings 🔑: - Troponin concentrations are 2⃣-times higher in patients with MACE compared to without - MACE is 4⃣-fold higher when troponin ›99th centile compared to <5 ng/L - A troponin concentration >10 ng/L increased likelihood of MACE by 50%
6
233
Ryan Wereski retweeted
A good opportunity to remind researchers that unadjusted Kaplan-Meier survival curves are mixtures of survival time distributions with strange weights, due to within-treatment variation of patient characteristics. #Statistics #clinicalresearch @vandy_biostat @EdgeforScholars
Friday night 🍺 after a very busy week of clinic, and wondering - why don’t we use Cox-Kalbfleisch-Prentice plots much more often and K-M rarely? These are more relevant and useful! 🤔 HT @f2harrell #rms
5
30
3
134
35,563
A masterpiece by @maciejbanach & colleagues of only 2-pages of which every line must be read. IF YOU FOLLOW ME - PROMISE TO READ ASAP - The paper so succinctly refutes every denier statement ever made. Free download ow.ly/tLjO50Pc8GN @nationallipid academic.oup.com/eurheartj/a…
33
89
7
361
72,778
Regression begins when you reach LDLc < 70 mg/dL (note that in the Nissen’s article the mean LDLc was > 94 mg/dL)
"Atherosclerosis regressed in patients with the greatest reduction in CRP levels, but not in those with the greatest reduction in LDL cholesterol levels".
5
28
3
98
36,841